Alto Neuroscience (ANRO) Operating Leases (2024 - 2026)

Alto Neuroscience has disclosed Operating Leases across 3 years of filings, most recently posting $3.6 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $3.6 million, down 19.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 million (down 19.41% YoY), and the FY2025 annual result was $3.8 million, down 29.02% from the prior year.
• Operating Leases came in at $3.6 million for Q1 2026 at Alto Neuroscience, down from $3.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $5.4 million in Q4 2024 to a low of $3.6 million in Q1 2026.
• The 3-year median for Operating Leases is $4.2 million (2025), against an average of $4.4 million.
• Across the five-year window, Operating Leases decreased 29.02% in 2025 and declined 19.41% in 2026, its largest moves.
• Alto Neuroscience's Operating Leases stood at $5.4 million in 2024, then fell by 29.02% to $3.8 million in 2025, then slipped by 7.01% to $3.6 million in 2026.
• The last three Operating Leases figures came in at $3.6 million (Q1 2026), $3.8 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.